[{"id":"view1-vision","name":"Maintained vision at Week 52 (lost <15 letters)","type":"PRIMARY","unit":"%","results":[{"notes":"Non-inferior to ranibizumab. Difference +0.6% (95.1% CI -3.2 to 4.4)","value":94,"arm_id":"eylea-q8w-view1","arm_name":"EYLEA 2mg Q8W"},{"value":95,"arm_id":"eylea-q4w-view1","arm_name":"EYLEA 2mg Q4W"},{"value":94,"arm_id":"ranibizumab-view1","arm_name":"Ranibizumab Q4W"}],"timepoint":"Week 52","description":"Proportion of patients losing fewer than 15 letters of visual acuity (ETDRS) from baseline at Week 52. Non-inferiority to ranibizumab (Lucentis)."}]

VIEW 1 met primary endpoint: EYLEA 2mg Q8W was non-inferior to ranibizumab Q4W (94% vs 94% maintained vision). Q8W dosing enabled less frequent injections with equivalent efficacy. Mean BCVA gain: +7.9 letters (EYLEA Q8W) vs +8.1 letters (ranibizumab Q4W).

VIEW 1 (n=1217): Injection-procedure-related AEs similar across arms. Conjunctival hemorrhage 25% vs 28%, eye pain 9% vs 9%, cataract 7% vs 7%, IOP increased 5% vs 7%. Endophthalmitis <0.1% per injection.

VIEW 1 established EYLEA as the dominant retina drug for a decade. The non-inferiority of Q8W vs monthly dosing was the commercial differentiator. Less burden on patients and retina clinics. Combined with VIEW 2, this led to EYLEA becoming a >$9B peak franchise.

EYLEA traps VEGF-A, VEGF-B, and PlGF vs ranibizumab which only targets VEGF-A. Q8W dosing hypothesis based on higher binding affinity.